FOLH1 and cancer: Long-term remission in those patients with B cell malignancies has been observed.2,3 In addition, a broad range of different cancer target antigens under clinical investigation using CAR-expressing T cells redirected against CD20, CD30, CD138, c-Met, EGFRvIII, ErbB2, FAB, GD2, HER2, WT1, PSMA, NY-ESO1, and others have been reviewed.4–6 In a similar way, both autologous and allogeneic natural killer (NK) effector cells,7 as well as the NK cell line NK-92, can be redirected against cancer.